Mereo BioPharma Group plc CEO Denise Scots-Knight's 2023 pay slips 1% to $2.2M
Mereo BioPharma Group plc reports 2023 executive compensation
By ExecPay News
Published: April 24, 2024
Mereo BioPharma Group plc reported fiscal year 2023 executive compensation information on April 24, 2024.
In 2023, three executives at Mereo BioPharma Group plc received on average a compensation package of $1.4M, a 8% increase compared to previous year.
Average pay of disclosed executives at Mereo BioPharma Group plc
Denise Scots-Knight, Chief Executive Officer, received $2.2M in total, which decreased by 1% compared to 2022. 47% of Scots-Knight's compensation, or $1M, was in option awards. Scots-Knight also received $254K in bonus, $565K in salary, $285K in stock awards, as well as $71K in other compensation.
Charles Sermon, General Counsel, received a compensation package of $1.1M, which increased by 15% compared to previous year. 38% of the compensation package, or $416K, was in salary.
Christine Fox, Chief Financial Officer, earned $1M in 2023, a 23% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 24, 2024.